L-arginine as a potential GLP-1-mediated immunomodulator of Th17-related cytokines in people with obesity and asthma

Shu-Yi Liao¹,² | Angela Linderholm³ | Megan R. Showalter⁴ | Ching-Hsien Chen³ | Oliver Fiehn⁴ | Nicholas J. Kenyon³,⁵

¹Department of Medicine, National Jewish Health, Denver, Colorado, USA
²Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
³Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of California-Davis, Sacramento, California, USA
⁴NIH West Coast Metabolomics Center, University of California-Davis, Davis, California, USA
⁵VA Northern California Health Care System (VANCHCS), Mather, California, USA

Abstract
Obesity is considered as a risk factor for COVID-19 with insulin resistance and increased production of inflammatory cytokines as likely mechanisms. Glucagon-like peptide-1 (GLP-1) agonists and inhaled nitric oxide are proposed therapeutic approaches to treat COVID-19 because of their broad anti-inflammatory effects. One approach that might augment GLP-1 levels would be dietary supplementation with L-arginine. Beyond cytokines, multiple studies have started to investigate the relationship between new-onset diabetes and COVID-19. In a posthoc analysis of a randomized, placebo-controlled human clinical trial of L-arginine supplementation in people with asthma and predominantly with obesity, the results showed that 12 weeks of continuous L-arginine supplementation significantly decreased the level of IL-21 (p = 0.02) and increased the level of insulin (p = 0.02). A high arginine level and arginine/ADMA ratio were significantly associated with lower CCL-20 and TNF-α levels. The study also showed that L-arginine supplementation reduces cytokine levels and improves insulin deficiency or resistance, both are two big risk factors for COVID-19 severity and mortality. Given its safety profile and ease of accessibility, L-arginine is an attractive potential therapeutic option that allows for a cost-effective way to improve outcomes in patients. An expedition of further investigation or clinical trials to test these hypotheses is needed.

Keywords
arginine, COVID-19, GLP-1, nitric oxide, Th17

1 | INTRODUCTION

The high mortality and morbidity of coronavirus disease in 2019 (COVID-19) has stimulated worldwide research to look into novel approaches to block the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or dampen the associated cytokine driven hyper-inflammatory response. Obesity is a risk factor for COVID-19 and increased insulin resistance, activation of the renin-angiotensin system, and increased inflammatory cytokines production may all be factors in host susceptibility.¹,² Glucagon-like peptide-1 (GLP-1) agonists have been proposed as potential therapies due to their strong anti-inflammatory effect in the lung, through the stimulation of the...
eNOS signaling cascade and the inactivation of the NF-κB pathway. Inhaled nitric oxide has also been similarly proposed as an approach to treat COVID-19 because of its effects on the vascular endothelium and potential direct antiviral activity. Nitric oxide also functions as an immunomodulator by modifying cytokine release from alveolar macrophages. To our knowledge, there is one clinical trial evaluating the effectiveness of GLP-1 agonist (semaglutide) on reducing complications of COVID-19 infection (ClinicalTrials.gov Identifier: NCT04615871) and many ongoing clinical trials evaluating the utility of inhaled nitric oxide to treat COVID-19 patients (ClinicalTrials.gov Identifier: NCT04476992, NCT04383002, NCT04338828, and NCT04397692).

Augmenting and sustaining nitric oxide levels and their effects in humans are challenging. Inhaled nitric oxide is not widely available outside of the intensive care unit and its costs remain prohibitively high. An indirect approach to augmenting nitric oxide levels is dietary supplementation with L-arginine, the substrate for nitric oxide, and a more cost-effective way to increase in vivo nitric oxide levels in patients with COVID-19. L-arginine supplementation can also increase the production of GLP-1 in both mice and humans and may work in a synergistic manner to reduce Th17-related cytokine production through nitric oxide. Th17 related cytokines are some of the candidates of interest in the cytokine storm and hyperinflammation of COVID-19. Th17 inflammatory responses play a critical role in the pathogenesis of COVID-19 induced pneumonia and the number of CCR6+ Th17 cells was found to be extraordinarily high in the peripheral blood of patients with severe COVID-19.

Findings of a randomized, placebo-controlled trial of L-arginine supplementation in severe asthmatics assigned prospectively to low and high exhaled nitric oxide groups were published recently. A predominant number of people in the cohort had obesity (BMI: 33.7 ± 8.6 [mean ± SD]) which allowed for secondary analysis of L-arginine, nitric oxide, and Th17-related cytokines. These factors are of interest in COVID-19. Multiple studies have also started to investigate the relationship between new-onset diabetes and COVID-19. A recent editorial proposed a potential diabetogenic effect of COVID-19, beyond the stress response that is secondary to the clinical illness. Two recent epidemiological studies also showed increases in COVID-19 related mortality in patients with diabetes. The mechanism remains unclear, but diabetes-related alterations in the angiotensin-converting enzyme 2 (ACE2) receptor may be causative. SARS CoV-2 can bind to the ACE2 receptor, expressed in several tissues, including the pancreas, and possibly lead to a new onset or worsening of pre-existing diabetes in patients with COVID-19. A recent clinical trial, DARE-19 (ClinicalTrials.gov Identifier: NCT 04350593), proposed the use of Dapagliflozin (a medication used to treat type 2 diabetes) for treating COVID-19, given its anti-inflammatory and insulin sensitivity-improving effects.

L-arginine has been shown to improve the integrity of pancreatic β-cells and islets in the presence of proinflammatory cytokines and increase insulin secretion and/or sensitivity in human and animal models. Activation of the GLP-1 receptor (GLP1R) also stimulates insulin secretion from pancreatic β-cells. Interestingly, oral L-arginine supplementation may have acute effects on insulin release mediated through GLP-1 as shown in mice. L-arginine supplementation has also been shown to increase postprandial circulating GLP-1 levels in humans. L-arginine supplementation therefore may be beneficial in COVID-19 patients due to its anti-inflammatory effects (directly or indirectly through GLP-1) and improvement of insulin secretion and sensitivity.

Aside from the beneficial effects of L-arginine supplementation, accumulation of asymmetric dimethylarginine (ADMA), a byproduct of protein modification that is closely related to L-arginine, can lead to impaired nitric oxide production. The arginine/ADMA ratio may represent arginine bioavailability and has been used as a marker for severity in cardiovascular diseases and asthma. In this study, a posthoc analysis of the previously published L-arginine supplementation in severe asthmatics clinical trial, outline the relationship between dietary L-arginine supplementation, GLP-1, insulin, nitric oxide levels, and Th17-related cytokines.

The hypotheses in the study are (1) L-arginine supplementation would reduce Th17 related cytokines and increase insulin levels, and (2) increased in vivo arginine levels, or arginine/ADMA ratios are associated with lower Th17-related cytokines and increased insulin levels.

2 METHODS

Study participants were drawn from the L-arginine interventional trial at the University of California-Davis (ClinicalTrials.gov Identifier: NCT01841281). Adult patients with severe asthma were included in the study. Briefly, subjects were on either controller treatment with high-dose inhaled corticosteroids or treatment with oral steroids more than 50% of the year. The detailed inclusion/exclusion criteria can be found in our previous publication. After informed consent, participants were randomized into the 30-weeks cross-over study trial. Each participant received Treatment A (L-arginine or placebo) for 12 weeks, then a 6-week washout period (not received either L-arginine or placebo), and finally another 12 weeks of Treatment B (e.g., if treatment A is L-arginine then Treatment B is placebo and vice versa). Subjects received placebo or L-arginine dosed orally at 0.05 mg/kg (ideal body weight) twice daily. With the cross-over study design, each subject acted as the subject’s control, and a smaller number of participants are required. Each subject had six visits (every 6 weeks) during the study period, during which the subject consented to a research blood draw (not fasting and not at a specific time). Stored frozen plasma was subjected to untargeted metabolomics by HILIC-QExactive HF mass spectrometry and GC-TOF MS performed as previously described. GLP-1, insulin, and cytokine levels were measured at visits 1, 3, 4, and 6 (start and end of each intervention period), and the concentrations of Th17-related cytokines, TNF-α, GLP-1, and insulin were determined using a Bio-Plex Pro Human TH17 Cytokine Assay (Bio-Rad) and Human Diabetes Bioplex Kit (Bio-Rad) according to the manufacturer’s protocol.
The analysis examined insulin and cytokine level changes correlated with L-arginine supplementation. GLP-1, insulin, and cytokine level changes between the final visit and the first visit of each intervention period were used as outcomes. For example, cytokine level (Visit 3) minus cytokine level (Visit 1) or cytokine level (Visit 6) minus cytokine level (Visit 4). A generalized linear mixed model was used for analysis, accounting for correlated repeated measurements in our crossover study design. Then, the association between the baseline (Visit 1) arginine-related metabolites and GLP-1, insulin, or cytokines were tested using a multivariate regression model adjusted for age, gender, race, and body mass index (BMI).

3 | RESULTS

A cohort of 19 participants that completed a total of six visits, were compliant with the L-arginine supplement, and underwent both metabolomic and cytokine measurements, were included in the final analysis. There were a total of 76 measurements of GLP-1, insulin, and cytokine levels (four measurements for each subject) and 19 baseline metabolomic measurements. The average age of all participants was 54.3 ± 12.1 years, they were female predominant (74%) and with obesity (74%, BMI: 33.7 ± 8.6).

3.1 | The treatment effect of L-arginine supplement on cytokine, GLP-1, or insulin concentration

The results showed that 12 weeks of chronic L-arginine supplementation significantly decreased the concentration of IL-21 by 18.99 pg/ml (p = 0.02) and increased the concentration of insulin by 585.76 pg/ml (p = 0.02) after 12 weeks of L-arginine supplement. The L-arginine supplement also decreased other cytokines and increased GLP-1 although did not reach the statistical significance (Table 1). Figure 1 showed boxplots of concentration change of cytokines, GLP-1, and insulin for each phase (placebo or treatment phase). Each dot represented an individual participant.

3.2 | Association between baseline arginine related metabolites levels and cytokine, GLP-1, or insulin level

Table 2 shows the results of the association between the baseline arginine-related metabolites levels and cytokine, insulin, or GLP-1 level. A higher arginine level was associated with lower CCL-20 (p = 0.03) and lower TNF-α (p = 0.03). A higher arginine/ADMA ratio was also found to be associated with lower CCL-20 (p = 0.004) and lower TNF-α (p = 0.03). A higher urea level was associated with higher GLP-1 (p = 0.0008). The arginine/ADMA ratio was also found to trend with lower IL-21 (p = 0.07). The scatter plots that showed the significant associations between arginine and arginine/ADMA ratio and cytokines (CCL-20, TNF-α) with the simple regression line (without covariates adjustment) are shown in Figure 2.

A post hoc power analysis was performed for those statistically significant findings. For the analysis of treatment effects and IL-21 or insulin (statistically significant). The powers were 0.90 and 0.99 respectively using Diggle et al.’s method. The power for the correlation between cytokines and metabolites is raged from 0.77 to 0.98 using Cohen et al.’s method.

4 | DISCUSSION

To the best of our knowledge, this is the first study to elucidate how L-arginine can serve as an immunomodulator and decrease Th17-related cytokines. It is also one of the few studies that demonstrates L-arginine supplementation increases insulin levels in people with asthma and obesity. The overlapping hypotheses derived from the shared biological pathways associated with L-arginine, GLP-1, and nitric oxide make it feasible to consider several approaches to

| Cytokines, GLP-1, insulin | Absolute concentration change after 12 weeks of L-arginine supplement (pg/ml) | p     |
|---------------------------|---------------------------------------------------------------------------------|------|
| IL-17F                    | -0.69                                                                           | 0.17 |
| IFN-γ                     | -19.24                                                                          | 0.18 |
| CCL20                     | -11.18                                                                          | 0.24 |
| IL-17A                    | -17.34                                                                          | 0.11 |
| IL-22                     | -0.70                                                                           | 0.15 |
| IL-21                     | -18.99                                                                          | 0.02 |
| TNF-α                     | -3.86                                                                           | 0.18 |
| GLP-1                     | 2.53                                                                            | 0.60 |
| Insulin                   | 585.76                                                                          | 0.02 |

Bold: statistically significant.
Abbreviation: GLP-1, glucagon-like peptide-1.
FIGURE 1  Boxplots of concentration change of cytokines, glucagon-like peptide-1 (GLP-1), and insulin for each phase (placebo or treatment phase). Each dot represented each individual.

TABLE 2  Associations between the cytokines, GLP-1, insulin, and intensities of arginine metabolism-related metabolites adjusted for sex, age, BMI, and race

| Cytokines, GLP-1, insulin | Arginine | ADMA | Citrulline | Ornithine | Urea | Arginine/ADMA |
|---------------------------|----------|------|------------|-----------|------|---------------|
|                           | Int*     | Int  | Int        | Int       | Int  | Int           |
| IL-17F                    | −3.6e−09 | 0.40 | 6.5e−07    | 0.76      | −3.5e−08| 0.32          | 1.9e−07 | 0.51 | 2.4e−05 | 0.96 |
| IFN-γ                     | −1.8e−06 | 0.18 | 1.0e−03    | 0.11      | −1.1e−05| 0.30          | 5.4e−05 | 0.55 | −2.6e−01| 0.10 |
| CCL20                     | −2.2e−06 | 0.03 | 6.1e−04    | 0.23      | 5.1e−07 | 0.95          | −2.4e−04| 0.66 | −3.0e−01| 0.004 |
| IL-17A                    | −9.3e−07 | 0.10 | 3.2e−04    | 0.26      | −2.2e−09| 0.65          | −2.8e−04| 0.35 | 2.9e−05 | 0.45 |
| IL-22                     | −1.1e−08 | 0.43 | 3.5e−06    | 0.61      | −6.9e−08| 0.53          | −4.9e−06| 0.48 | 3.0e−07 | 0.74 |
| IL-21                     | −1.8e−06 | 0.16 | 8.4e−04    | 0.17      | −2.9e−06| 0.78          | −6.5e−04| 0.31 | 3.0e−05 | 0.72 |
| TNF-α                     | −5.6e−07 | 0.03 | 1.8e−04    | 0.17      | −2.3e−07| 0.92          | −7.0e−05| 0.62 | 3.1e−06 | 0.87 |
| GLP-1                     | 1.3e−07  | 0.35 | −6.43e−05  | 0.34      | −1.7e−06| 0.12          | −6.4e−05| 0.36 | 2.5e−05 | <0.001|
| Insulin                   | 8.75e−06 | 0.89 | 3.2e−03    | 0.68      | 4.5e−05 | 0.56          | 4.9e−03 | 0.44 | −2.6e−04| 0.67 |

Note: The bold values indicate p <0.05.

Abbreviations: BMI, body mass index, GLP-1, glucagon-like peptide-1.2

*Int: Intensity; The level is the intensity, not the absolute concentration.
L-arginine may suppress Th17-related cytokines through an increase of nitric oxide while synergetically increasing GLP-1, which also results in increased nitric oxide. This relationship may also have a direct anti-inflammatory effect through the NF-kB pathway. Nitric oxide has been shown to suppress the proliferation and function of human Th17 cells. By suppressing the COVID-19 responsive cytokine IL-21, the B cell differentiation and cytotoxic program of natural killer cells are reduced and this may reduce the severity of acute respiratory distress syndrome. Higher arginine levels and arginine/ADMA ratios are both associated with lower CCL-20 and TNF-α. CCL-20 is a ligand for CCR6, a part of the chemotaxis system which is induced in response to SARS-CoV infection, and enhances Th17-mediated inflammation through immune cell trafficking. Anti-TNF-α therapy has been proposed as another potential therapy due to TNF-α’s action as an amplifier of inflammation and key cytokine of acute inflammation. Nitric oxide can directly inhibit TNF-α secretion whereas GLP-1 indirectly inhibits TNF-α secretion through increasing nitric oxide levels and inhibition of the NF-kB pathway. Arginine supplementation inhibits TNF-α synthesis through the induction of arginase activity, supporting our hypothesis. Anti-TNF agents have been proposed as a therapy for COVID-19 since TNF is a major cytokine that causes hyperinflammation. Suppression of TNF may reduce the inflammation-driven capillary leak found in some COVID-19 patients.

This study also supported that L-arginine supplementation may increase insulin secretion, observed in a previous rat model. The
The biological pathway between arginine, glucagon-like peptide-1 (GLP-1), insulin, nitric oxide, and TH17-related cytokines

The effect of increased insulin levels may be directly linked to L-arginine supplementation or indirectly working through synergetic effects with GLP-1 since GLP-1 can also increase insulin secretion in pancreas β cells.

There are several limitations worth noting. First, although it is a randomized clinical trial, L-arginine supplementation was implemented over 12 weeks and may not directly be applied to the acute setting without a dosage adjustment. Second, the clinic participants were enrolled before the COVID-19 pandemic and further clinical trials are needed to specifically evaluate the effects of arginine supplementation in patients with COVID-19. Finally, these findings are generated in patients with severe asthma and should be applied with caution for patients without asthma.

This study showed that L-arginine supplementation can reduce the cytokines and improve insulin deficiency or resistance which are two big risk factors for COVID-19 severity and mortality. Given its safety profile and ease of accessibility, L-arginine is an attractive potential therapeutic option that allows for a cost-effective way to improve outcomes in patients. An expedition of further investigation or clinical trials to test these hypotheses is needed.

**ACKNOWLEDGMENTS**

This work was supported by NIH: 5R01HL105573-03 and TRDRP 28IR-0051.

**CONFLICT OF INTERESTS**

The authors declare that there are no conflict of interests.

**AUTHOR CONTRIBUTIONS**

Shu-Yi Liao, Angela Linderholm, Megan R Showalter, Ching-Hsien Chen, Oliver Fiehn, and Nicholas J. Kenyon wrote the manuscript. Shu-Yi Liao developed the analysis plan and performed the data analysis. Angela Linderholm and Nicholas J. Kenyon designed the study and wrote the grant. Angela Linderholm and Megan R Showalter performed sample handling and metabolomic profiling. Nicholas J. Kenyon and Oliver Fiehn supervised the research.

**ORCID**

Shu-Yi Liao https://orcid.org/0000-0001-9477-3837

**REFERENCES**

1. Lim S, Shin SM, Nam GE, Jung CH, Koo BK. Proper management of people with obesity during the COVID-19 pandemic. J Obes Metab Syndr. 2020;29(2):84–98. https://doi.org/10.7570/jomes20056.

2. Engin AB, Engin ED, Engin A. Two important controversial risk factors in SARS-CoV-2 infection: obesity and smoking. Environ Toxicol Pharmacol. 2020;78:103411. https://doi.org/10.1016/j.etap.2020.103411.

3. Jin T, Liu M. Letter to the editor: comment on GLP-1-based drugs and COVID-19 treatment. Acta Pharm Sin B. 2020;10(7):1249–1250. https://doi.org/10.1016/j.apsb.2020.05.006.

4. Zamanian RT, Pollack CV Jr., Gentile MA, et al. Outpatient inhaled nitric oxide in a patient with vasoreactive IPAH and COVID-19 infection. Am J Respir Crit Care Med. 2020;202:130–132. https://doi.org/10.1164/rrccm.202004-0937LE.

5. Thomassen MJ, Buhrow LT, Connors MJ, Kaneko FT, Erzurum SC, Kavuru MS. Nitric oxide inhibits inflammatory cytokine production by human alveolar macrophages. Am J Respir Cell Mol Biol. 1997;17(3):279–283. https://doi.org/10.1165/ajrcmb.17.3.2998m.

6. Clemmensen C, Smajilovic S, Smith EP, et al. Oral L-arginine stimulates GLP-1 secretion to improve glucose tolerance in male mice. Endocrinology. 2013;154(11):3978–3983. https://doi.org/10.1210/en.2013-1529.

7. Amin A, Neophytou C, Thein S, et al. L-Arginine increases post-prandial circulating GLP-1 and PYY levels in humans. Obesity. 2018;26(11):1721–1726. https://doi.org/10.1002/oby.22323.

8. Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect. 2020;53:368–370. https://doi.org/10.1016/j.jmii.2020.03.005.

9. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422. https://doi.org/10.1016/S2213-2600(20)30076-X.

10. Liao SY, Showalter MR, Linderholm AL, et al. L-arginine supplementation in severe asthma. JCI Insight. 2020;5:e137777. https://doi.org/10.1172/jci.insight.137777.

11. Rubino F, Amiel SA, Zimmet P, et al. New-onset diabetes in Covid-19. N Engl J Med. 2020;383(8):789–790. https://doi.org/10.1056/NEJMoa2018688.

12. Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020;8(10):813–822. https://doi.org/10.1016/S2213-8587(20)30272-2.

13. Holman N, Knighton P, Kar P, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020;8(10):823–833. https://doi.org/10.1016/S2213-8587(20)30271-0.

14. Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020;8(9):782–792. https://doi.org/10.1016/S2213-8587(20)30238-2.

15. Liu F, Long X, Zhang B, Zhang W, Chen X, Zhang Z. ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection. Clin Gastroenterol Hepatol. 2020;18(9):2128–2130. https://doi.org/10.1016/j.cgh.2020.04.040.
26. Krause MS, McClanahan NH, Flatt PR, de Bittencourt PI, Murphy C, Newsholme P. L-arginine is essential for pancreatic beta-cell functional integrity, metabolism and defense from functional challenge. *J Endocrinol*. 2011;211(1):87–97. https://doi.org/10.1530/JOE-11-0236.

27. Miczek A, Suliburska J, Pupek-Musialik D, et al. Effect of L-arginine supplementation on insulin resistance and serum adiponectin concentration in rats with fat diet. *Int J Clin Exp Med*. 2015;8(7):10358–10366.

28. Adeghe E, Poney AS, El-Sharkawy T, Parvez H. L-arginine stimulates insulin secretion from the pancreas of normal and diabetic rats. *Amino Acids*. 2001;21(2):205–209. https://doi.org/10.1007/s007260170028.

29. Piatti PM, Monti LD, Valsecchi G, et al. Long-term oral L-arginine administration improves peripheral and hepatic insulin sensitivity in type 2 diabetic patients. *Diabetes Care*. 2001;24(5):875–880. https://doi.org/10.2337/diacare.24.5.875.

30. Meloni AR, DeYoung MB, Lowe C, Parkes DG. GLP-1 receptor activated insulin secretion from pancreatic beta-cells: mechanism and glucose dependence. *Diabetes Obes Metab*. 2013;15(1):15–27. https://doi.org/10.1111/j.1463-1326.2012.01663.x.

31. Sibai L, Agarwal SC, Home PD, Boger RH. The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. *Curr Cardiol Rev*. 2010;6(2):82–90. https://doi.org/10.2174/157340310791162659.

32. Bratt JM, Zeki AA, Last JA, Kenyon NJ. Competitive metabolism of L-arginine: arginase as a therapeutic target in asthma. *J Biomed Res*. 2011;25(5):299–308. https://doi.org/10.1016/S1674-8301(11)60041-9.

33. Linderholm AL, Bratt JM, Schuster GJ, Zeki AA, Kenyon NJ. Novel therapeutic strategies for adult obese asthmatics. *Immunol Allergy Clin North Am*. 2014;34(4):809–823. https://doi.org/10.1016/j.iac.2014.07.006.

34. Bode-Boger SM, Scalera F, Ignarro LJ. The L-arginine paradox: importance of the L-arginine/asymmetrical dimethylarginine ratio. *Pharmacol Ther*. 2007;114(3):295–306. https://doi.org/10.1016/j.pharmthera.2007.03.002.

35. Holguín F, Comhair SA, Hazen SL, et al. An association between L-arginine/asymmetric dimethyl arginine balance, obesity, and the age of asthma onset phenotype. *Am J Respir Crit Care Med*. 2013;187(2):153–159. https://doi.org/10.1164/rccm.201207-1270OC.

36. Diggle P, Heagerty P, Liang K, Zeger S. *Analysis of Longitudinal Data*. 2nd ed. Oxford University Press. 2002.

37. Cohen J, Cohen P, West SG, Aiken LS. *Applied Multiple Regression/Correlation Analysis for the Behavioral Sciences*. 3rd ed. Lawrence Earlbaum Associates. 2003.

38. Niemela W, Alves-Filho JC, Fukada SY, et al. Regulation of type 17 helper T-cell function by nitric oxide during inflammation. *Proc Natl Acad Sci U S A*. 2011;108(22):9220–9225. https://doi.org/10.1073/pnas.1100667108.

39. Maddur MS, Miossec P, Kaveri SV, Bayry J. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. *Am J Pathol*. 2012;181(1):8–18. https://doi.org/10.1016/j.ajpath.2012.03.044.

40. Feldmann M, Maini RN, Woody JN, et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. *Lancet*. 2020;395(10234):1407–1409. https://doi.org/10.1016/S0140-6736(20)30858-8.

41. Lee YS, Jun HS. Anti-inflammatory effects of GLP-1-based therapies beyond glucose control. *Mediat Inflamm*. 2016;2016:3094642. https://doi.org/10.1155/2016/3094642.

42. Quirino IE, Carneiro MB, Cardoso VN, et al. Arginine supplementation induces arginase activity and inhibits TNF-alpha synthesis in mice spleen macrophages after intestinal obstruction. *J Parenter Enter Nutr*. 2016;40(3):417–422. https://doi.org/10.1177/0148607114564374.

---

**How to cite this article:** Liao SY, Linderholm A, Showalter MR, Chen CH, Fiehn O, Kenyon NJ. L-arginine as a potential GLP-1-mediated immunomodulator of Th17-related cytokines in people with obesity and asthma. *Obes Sci Pract*. 2021;7:339–345. [https://doi.org/10.1002/osp4.500](https://doi.org/10.1002/osp4.500)